Long-term Study of DSP-5423P in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates the long term safety of DSP-5423P in patients with schizophrenia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sumitomo Dainippon Pharma Co., Ltd.

Criteria

Inclusion Criteria:

• Patients who have schizophrenia diagnosed by DSM-5, diagnostic criteria

• Patients who are aged 18 years or older at informed consent

• Patient understands the objectives and procedures of the study and who provide written voluntarily consent to participate in the study, etc.

Exclusion Criteria:

• Patients who fall under a contraindication listed in the LONASEN® package insert

• Patients with Parkinson disease, etc.